I agree with you that diversification needs to be a major consideration in building a portfolio. Also, apart from the well-documented doubts associated with the darker areas of NNVC's history and the involvement of CTIX's management, the CTIX chart moved sluggishly and stayed range-bound for most of this year. On the other hand, the chart has moved aggressively to the upside since it touched the mid $1.40s, and appears ready to challenge resistance at $2.00.

Three months ago I reduced my holding in CTIX by about half, but the next probable move would be to add in anticipation of the next two or three PRs on Kevetrin. The progress reported so far on the trials at Dana-Farber could hardly have gone better or more smoothly. The chances of significant developments with Kevetrin in 2014 now seem very high.

In general, I appreciate your apparently inexhaustible calm and equanimity in assessing CTIX's prospects.